Results by group50

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 50

Outcome	Group	Value	Spread	Units
Total Symptom Score (TSS) Response Rate at Week 24	MMB 200 mg QD + Placebo	24.62	95% Confidence Interval 17.49 to 32.94	Percentage of participants
Total Symptom Score (TSS) Response Rate at Week 24	DAN 300 mg BID + Placebo	9.23	95% Confidence Interval 3.46 to 19.02	Percentage of participants
Percentage of Participants With Transfusion Independence (TI) at Week 24	MMB 200 mg QD + Placebo	30.0	95% Confidence Interval 22.28 to 38.66	Percentage of Participants
Percentage of Participants With Transfusion Independence (TI) at Week 24	DAN 300 mg BID + Placebo	20.00	95% Confidence Interval 11.10 to 31.77	Percentage of Participants
Splenic Response Rate (SRR) of >=25% at Week 24	MMB 200 mg QD + Placebo	39.23	95% Confidence Interval 30.79 to 48.18	Percentage of Participants
Splenic Response Rate (SRR) of >=25% at Week 24	DAN 300 mg BID + Placebo	6.15	95% Confidence Interval 1.70 to 15.01	Percentage of Participants
Change From Baseline in MFSAF TSS at Week 24	MMB 200 mg QD + Placebo	-9.36	Standard Error 1.08	Scores on a scale
Change From Baseline in MFSAF TSS at Week 24	DAN 300 mg BID + Placebo	-3.13	Standard Error 1.62	Scores on a scale
Splenic Response Rate (SRR) of >= 35% at Week 24	MMB 200 mg QD + Placebo	22.31	95% Confidence Interval 15.48 to 30.44	Percentage of Participants
Splenic Response Rate (SRR) of >= 35% at Week 24	DAN 300 mg BID + Placebo	3.08	95% Confidence Interval 0.37 to 10.68	Percentage of Participants
Percentage of Participants With Zero RBC Units Transfused Over 24-Weeks	MMB 200 mg QD + Placebo	35.38	95% Confidence Interval 27.20 to 44.25	Percentage of participants
Percentage of Participants With Zero RBC Units Transfused Over 24-Weeks	DAN 300 mg BID + Placebo	16.92	95% Confidence Interval 8.76 to 28.27	Percentage of participants
Percentage of Participants With <=4 RBC Units Transfused Over 24-weeks	MMB 200 mg QD + Placebo	55.38	95% Confidence Interval 46.42 to 64.10	Percentage of participants
Percentage of Participants With <=4 RBC Units Transfused Over 24-weeks	DAN 300 mg BID + Placebo	44.62	95% Confidence Interval 32.27 to 57.47	Percentage of participants
Duration of MFSAF TSS Response	MMB 200 mg QD + Placebo	286.00	Inter-Quartile Range 286.00 to 286.00	Days
Duration of MFSAF TSS Response	DAN 300 mg BID + Placebo	NA	Inter-Quartile Range NA to NA	Days
Duration of TI Response	MMB 200 mg QD + Placebo	NA	Inter-Quartile Range NA to NA	Days
Duration of TI Response	DAN 300 mg BID + Placebo	NA	Inter-Quartile Range NA to NA	Days
Mean Cumulative Number of Whole Blood Units Transfused Over 24 Weeks	MMB 200 mg QD + Placebo	6.55	Standard Deviation 8.413	Whole blood units
Mean Cumulative Number of Whole Blood Units Transfused Over 24 Weeks	DAN 300 mg BID + Placebo	10.86	Standard Deviation 13.203	Whole blood units

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04173494/results

API reference For AI assistants

Results by group50

Sources 3

Read this list from software.